Anthranilamide inhibitors of aurora kinase
The present invention relates to a compound represented by the following formula: or a pharmaceutically acceptable salt thereof; wherein R 1 , R 1′ R 2 , R 3 , R 4 , R 5 , r and s are as defined herein. Compounds of the present invention are useful in the treatment of diseases associated with Aurora kinase activity such as cancer.
1. A compound selected from the group consisting of:
2-{[5-Fluoro-2-({3-[2-(4-morpholinyl)ethyl]phenyl}amino)-4-pyrimidinyl]amino}-N-(2-hydroxyethyl)benzamide;
(3R)-1-({2-[(5-fluoro-2-{[3-(4-methyl-1-piperazinyl)phenyl]amino}-4-pyrimidinyl)amino]phenyl}carbonyl)-3-pyrrolidinol;
(3R)-1-[(2-{[5-Methyl-2-({3-[2-(4-morpholinyl)ethyl]phenyl}amino)-4-pyrimidinyl]amino}phenyl)carbonyl]-3-pyrrolidinol;
2-[(2-{[4-({[2-(ethylamino)ethyl]sulfonyl}methyl)phenyl]amino}-5-fluoro-4-pyrimidinyl)amino]-N-(1-methylethyl)benzamide;
2-[(5-fluoro-2-{[4-(4-piperidinyl)phenyl]amino}-4-pyrimidinyl)amino]-N-(1-methylethyl)benzamide; and
2-[(5-fluoro-2-{[4-({[2-(methylsulfonyl)ethyl]amino}methyl)phenyl]amino}-4-pyrimidinyl)amino]-N-(1-methylethyl)benzamide.
2. A pharmaceutically acceptable salt of the compound of claim 1 .
3. A composition comprising a) the compound of claim 1 or a pharmaceutically acceptable salt thereof; and b) at least one pharmaceutically acceptable excipient.